{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination significantly broadens the repertoire of tumor antigens presented on MHC-I molecules.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination",
          "line_ref": "L28"
        },
        {
          "quote": "Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape",
          "line_ref": "L29"
        }
      ],
      "caveat": "The immunopeptidomic analysis was performed in mouse models, and while robust, may not perfectly reflect the human tumor microenvironment."
    },
    {
      "claim_id": "C02",
      "claim": "The mechanism by which intratumoral mRNA sensitizes tumors to ICI is dependent on the induction of Type I interferon signaling pathways.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors",
          "line_ref": "L31"
        },
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        }
      ],
      "caveat": "The direct causal link was proven using an antibody blockade control in the preclinical mouse model, not in the human retrospective cohort."
    },
    {
      "claim_id": "C03",
      "claim": "The combination of intratumoral mRNA vaccination and anti-PD-L1 therapy leads to increased immune cell infiltration and improved tumor control compared to either monotherapy.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy",
          "line_ref": "L33"
        },
        {
          "quote": "Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.",
          "line_ref": "L36"
        }
      ],
      "caveat": "Efficacy experiments were conducted in murine models, and the retrospective human data suggesting benefit is prone to residual confounding."
    },
    {
      "claim_id": "C04",
      "claim": "Patients who received prior SARS-CoV-2 mRNA vaccination showed a statistically improved survival outcome when subsequently treated with immune checkpoint blockade.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        },
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        }
      ],
      "caveat": "This finding is subject to significant validity threats as the human analysis is retrospective, non-randomized, and complicated by heterogeneity in tumor types and treatment history."
    }
  ]
}